RxDoctor Payments DataLook up a doctor →

Jason Schoenfeld, MD

MOHS-Micrographic Surgery · Philadelphia, PANPI 1942647078

Payments from drug & device makers

$959,557in general payments, 2019–2025

Across 1,069 payments — averaging $897.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$405K
  • Sanofi US Services Inc.$323K
  • Janssen Research & Development, LLC$199K
  • Eli Lilly$16K
  • Johnson & Johnson$4K
  • Sun Pharmaceutical Industries Inc.$4K
  • plus $9K from 38 others

What the payments were for

  • Consulting fees$2,80014%
  • Travel & lodging$1311%
  • Food & beverage$17,08685%
  • Education$1871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$959,557 in reported general payments places this provider in the 95th percentile of 48 mohs-micrographic surgery providers in Pennsylvania.

See all mohs-micrographic surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,263,739
Medicare patients
1,011
Services billed
6,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyriziRisankizumab-Rzaa28$562,964
TremfyaGuselkumab24$324,247
Dupixent SyringeDupilumab72$284,919
Dupixent PenDupilumab45$167,064
RinvoqUpadacitinib15$93,534
Clobetasol Propionate189$11,601
Tacrolimus49$7,905
Ketoconazole309$4,995
Triamcinolone Acetonide189$3,215
Gentamicin Sulfate100$3,143
Doxycycline Hyclate512$3,026
Fluorouracil41$2,508
Hydrocortisone166$2,457
Dapsone12$1,797
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc22$939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi, Rinvoq$404,996$656,49843 claims
Johnson & JohnsonTremfya$4,135$324,24724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 mohs-micrographic surgery providers in Pennsylvania.

Other mohs-micrographic surgery in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →